Therapeutic Classification: antipsychotics, mood stabilizers
Pharmacologic Classification: piperazine derivatives
BEERS REMS
Absorption: 60% absorbed following oral administration; 100% absorbed from IM sites.
Distribution: Well distributed to tissues.
Protein Binding: 99%.
Half-Life: PO: 7 hr; IM: 25 hr.
(plasma concentrations)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | within hrs | 13 days‡ | unknown |
IM | rapid | 60 min | unknown |
‡Steady state achieved following continuous use.
Contraindicated in:
Use Cautiously in:
CV: orthostatic hypotension, QT interval prolongation
Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), rash, STEVENS-JOHNSON SYNDROME (SJS), urticaria
EENT: rhinorrhea
Endo: galactorrhea, hyperglycemia
GI: constipation, diarrhea, nausea, dysphagia
GU: amenorrhea, impotence
Hemat: AGRANULOCYTOSIS, leukopenia, neutropenia
Neuro: dizziness, drowsiness, restlessness, extrapyramidal reactions, NEUROLEPTIC MALIGNANT SYNDROME, seizures, syncope, tardive dyskinesia
Resp: cough
Drug-drug:
Schizophrenia
Acute Manic or Mixed Episodes Associated with Bipolar I Disorder
Maintenance Treatment of Bipolar I Disorder (as adjunct to lithium or valproate)
Lab Test Considerations:
NDC Code